Somewhere in the long human effort to ease suffering that comes from the body turning on itself, a compound drawn from the bark of a tree that has long served traditional Chinese medicine has now shown, in rats, that it can calm swollen joints and slow their destruction. Reported in the journal Engineering, the finding belongs for now to the laboratory and the animal model rather than the clinic. Its significance lies less in any cure than in a new pathway it points toward: an enzyme called ACOT1, and the correction of fatty acid metabolism that the compound appears to restore, offering resear
Plant Compound Obakulactone Reduces Arthritis Symptoms in Rats, Targets Fatty Acid Metabolism
Rats, isolated cells, and a possible new target called ACOT1
Mark
So what's actually new here? Plant extracts for arthritis aren't unusual.
Mimi
The mechanism. The team says OL binds ACOT1, an enzyme tied to fatty acid metabolism, and that this reduces SCD1 and dampens JAK-STAT and PI3K-AKT signaling.
Mark
And the animal results?
Mimi
Rats given 50, 100 or 200 mg/kg daily for 21 days showed less joint swelling, better cartilage and synovium structure, and lower inflammatory markers in a dose-dependent way.
Luke
Worth saying clearly: that's rats with arthritis induced by Freund's adjuvant, plus isolated cells. It's not a human trial.
Mark
Does the rat model resemble human disease closely?
Luke
The source doesn't say how well it translates, and I won't guess. It only says more studies are needed for safety and efficacy in people.
Mimi
The binding data came from several lab methods, including surface plasmon resonance, which gives the 6.2 micromolar figure.
Luke
That figure is the authors' own measurement. Nothing here shows independent replication.
Mark
So why does it matter?
Mimi
Because ACOT1 could be a new drug target, and the authors note current treatments don't work for everyone and can have serious side effects.
Luke
'Could be' is carrying the sentence. It's a hypothesis worth watching, not a treatment.
El Pulso
- Rheumatoid arthritis, an autoimmune disease that turns the immune system against healthy joint tissue, sets the urgency here, with pain, swelling and progressive damage mounting in affected joints.
- In arthritic rats, a compound called obakulactone, isolated from Phellodendri cortex bark, sharply reduced joint swelling and inflammation and restored cartilage and synovial structure.
- Inflammatory signals such as IL-6 and TNF-α fell in a dose-dependent way, while overactive immune cells and inflammatory macrophages were pulled back toward a calmer state.
- The compound binds the enzyme ACOT1, prompting its breakdown and quieting the JAK-STAT and PI3K-AKT signaling that drives the inflammation.
- The trajectory stops at the animal model: human safety and effectiveness remain untested, and whether ACOT1 proves a worthwhile drug target is the question still ahead.
Somewhere in the long human effort to ease suffering that comes from the body turning on itself, a compound drawn from the bark of a tree that has long served traditional Chinese medicine has now shown, in rats, that it can calm swollen joints and slow their destruction. Reported in the journal Engineering, the finding belongs for now to the laboratory and the animal model rather than the clinic. Its significance lies less in any cure than in a new pathway it points toward: an enzyme called ACOT1, and the correction of fatty acid metabolism that the compound appears to restore, offering researchers a possible new door into a disease that affects roughly one in every hundred people.
A compound pulled from the bark of a tree long used in traditional Chinese medicine has eased swelling and joint destruction in rats with rheumatoid arthritis, according to a study published in the journal Engineering. The compound, called obakulactone, is so far tested only in animals and isolated cells.
Rheumatoid arthritis is a chronic autoimmune condition in which the immune system attacks healthy joint tissue, causing pain, stiffness and progressive damage. Researchers induced the disease in rats and treated them for 21 days with three doses of the compound. Joint swelling fell significantly, and the cartilage and the synovium lining the joints began to recover their normal structure.
Blood tests showed lower levels of inflammatory molecules and disease markers, and inside the joints the compound reduced overactive immune cells and nudged macrophages away from their inflammatory state. Further analysis showed that the disease had disrupted how the body produces and processes certain fatty acids, and the compound helped correct those disruptions.
Laboratory work indicated that the compound binds directly to an enzyme called ACOT1, prompting its breakdown and reducing a chain of signals that drive inflammation. The authors suggest ACOT1 could become a new drug target, and that correcting fatty acid metabolism might one day form a treatment strategy. The study stresses that these are preliminary findings, and that human safety and efficacy have yet to be established.
A compound pulled from the bark of a tree used in traditional Chinese medicine eased swelling and joint destruction in rats with a model of rheumatoid arthritis, according to a study published in the journal Engineering. The compound is called obakulactone, or OL, and the work behind it is entirely preclinical.
OL is a tetracyclic triterpenoid isolated from the bark of Phellodendri cortex. That bark has a long history in traditional medicine and contains OL alongside other constituents, according to Yang Jin's account in an introduction to Chinese materia medica. The researchers set out to test whether the isolated compound could act on rheumatoid arthritis, a chronic autoimmune disease that the study says affects about 1% of people worldwide. In it, the immune system attacks healthy joint tissue, producing pain, swelling, stiffness and progressive damage.
The team induced arthritis in rats using complete Freund's adjuvant, then gave the animals OL for 21 days at three dose levels: 50, 100 and 200 milligrams per kilogram per day. Treatment significantly reduced joint swelling and helped restore the normal structure of cartilage and of the synovium, the tissue that lines the joints.
Blood work showed dose-dependent drops in inflammatory molecules, including IL-1β, IL-6, IL-17 and TNF-α, along with markers used to track rheumatoid arthritis: RF, CCP-Ab, CRP and MMP-3. Inside the joints, the compound lowered abnormally high levels of CD3+ T cells and CD68+ macrophages. It also shifted macrophages away from the proinflammatory M1 state and toward the anti-inflammatory M2 state.
The researchers then looked at mechanism. Multiomics analysis showed that the disease disrupted the production and metabolism of several unsaturated fatty acids, and OL helped correct those abnormalities. The compound slowed the growth of abnormal synovial fibroblasts, pushed them toward apoptosis, and cut their release of inflammatory cytokines.
Laboratory experiments, including cellular thermal shift assays, microscale thermophoresis and surface plasmon resonance, indicated that OL binds directly to an enzyme called ACOT1, with a dissociation constant of about 6.2 micromoles per liter. By promoting the breakdown of ACOT1 through the ubiquitin–proteasome pathway, OL lowered levels of the downstream molecule SCD1 and limited activation of the JAK-STAT and PI3K-AKT signaling pathways, the authors reported.
On that basis, the authors identify ACOT1 as a potential new drug target and suggest that correcting fatty acid metabolism could become a treatment strategy. Their background notes that existing therapies do not work equally well for everyone and can cause serious adverse effects. "The findings provide preclinical evidence that OL could serve as a potential therapeutic compound for rheumatoid arthritis," they wrote.
The limits are plain. The experiments were done in rats and isolated cells, and the report states that further studies are needed to establish safety and efficacy in humans. What to watch is whether ACOT1 holds up as a target in later work, and whether anything here moves beyond the animal model.
Citas Notables
The findings provide preclinical evidence that OL could serve as a potential therapeutic compound for rheumatoid arthritis.— Study authors, Engineering
Quieres la nota completa?
Lee el original en Natural News ↗
Science & Space